Gerald E. Hanks

24.7k total citations · 4 hit papers
393 papers, 19.4k citations indexed

About

Gerald E. Hanks is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Gerald E. Hanks has authored 393 papers receiving a total of 19.4k indexed citations (citations by other indexed papers that have themselves been cited), including 263 papers in Pulmonary and Respiratory Medicine, 139 papers in Radiation and 85 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Gerald E. Hanks's work include Prostate Cancer Diagnosis and Treatment (198 papers), Prostate Cancer Treatment and Research (178 papers) and Advanced Radiotherapy Techniques (138 papers). Gerald E. Hanks is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (198 papers), Prostate Cancer Treatment and Research (178 papers) and Advanced Radiotherapy Techniques (138 papers). Gerald E. Hanks collaborates with scholars based in United States, Canada and Japan. Gerald E. Hanks's co-authors include William U. Shipley, Alexandra L. Hanlon, Howard M. Sandler, Timothy E. Schultheiss, Eric M. Horwitz, W. Robert Lee, Mack Roach, Howard D. Thames, Simon Krämer and Rachelle Lanciano and has published in prestigious journals such as Nature, JAMA and Journal of Clinical Oncology.

In The Last Decade

Gerald E. Hanks

386 papers receiving 18.7k citations

Hit Papers

Defining biochemical failure following radiotherapy with ... 1997 2026 2006 2016 2006 2003 1997 2008 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
    2006 2.1k citations Mack Roach, Gerald E. Hanks et al. International Journal of Radiation Oncology*Biology*Physics profile →
  2. Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
    2003 526 citations Gerald E. Hanks, Eric M. Horwitz et al. Journal of Clinical Oncology profile →
  3. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
    1997 492 citations Miljenko V. Pilepich, Roger W. Byhardt et al. Journal of Clinical Oncology profile →
  4. Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer
    2008 488 citations Eric M. Horwitz, Kyounghwa Bae et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gerald E. Hanks United States 76 13.9k 6.6k 3.9k 3.3k 2.2k 393 19.4k
Alvaro A. Martinez United States 75 9.3k 0.7× 9.9k 1.5× 2.8k 0.7× 5.4k 1.6× 1.9k 0.9× 393 17.2k
Michael J. Zeléfsky United States 92 21.5k 1.5× 12.5k 1.9× 6.6k 1.7× 6.2k 1.9× 4.0k 1.8× 544 29.3k
William U. Shipley United States 79 14.2k 1.0× 5.4k 0.8× 9.9k 2.6× 2.2k 0.7× 3.8k 1.7× 401 23.8k
Ennapadam Venkatraman United States 62 8.1k 0.6× 2.6k 0.4× 3.6k 0.9× 2.0k 0.6× 3.3k 1.5× 116 13.2k
William T. Sause United States 50 8.3k 0.6× 2.3k 0.4× 2.3k 0.6× 1.8k 0.5× 4.7k 2.1× 173 12.3k
David P. Dearnaley United Kingdom 73 11.3k 0.8× 4.6k 0.7× 4.3k 1.1× 5.0k 1.5× 3.7k 1.6× 416 18.4k
M. Bolla France 50 16.6k 1.2× 3.3k 0.5× 5.1k 1.3× 3.2k 1.0× 4.6k 2.1× 231 22.9k
Luís Souhami Canada 51 8.5k 0.6× 2.5k 0.4× 3.5k 0.9× 2.2k 0.7× 3.3k 1.5× 348 15.9k
Guy Storme Belgium 48 6.0k 0.4× 4.1k 0.6× 1.7k 0.4× 2.9k 0.9× 2.2k 1.0× 255 10.8k
Anthony L. Zietman United States 66 10.6k 0.8× 4.0k 0.6× 5.6k 1.4× 1.8k 0.6× 2.9k 1.3× 330 16.8k

Countries citing papers authored by Gerald E. Hanks

Since Specialization
Citations

This map shows the geographic impact of Gerald E. Hanks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald E. Hanks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald E. Hanks more than expected).

Fields of papers citing papers by Gerald E. Hanks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald E. Hanks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald E. Hanks. The network helps show where Gerald E. Hanks may publish in the future.

Co-authorship network of co-authors of Gerald E. Hanks

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald E. Hanks. A scholar is included among the top collaborators of Gerald E. Hanks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald E. Hanks. Gerald E. Hanks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamstra, Daniel A., Kyounghwa Bae, Gerald E. Hanks, et al.. (2014). Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 121(6). 844–852. 2 indexed citations
2.
Smith, Matthew R., Kyounghwa Bae, Jason A. Efstathiou, et al.. (2008). Diabetes and Mortality in Men With Locally Advanced Prostate Cancer: RTOG 92-02. Journal of Clinical Oncology. 26(26). 4333–4339. 47 indexed citations
3.
4.
Roach, Mack, Gerald E. Hanks, Howard D. Thames, et al.. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology*Biology*Physics. 65(4). 965–974. 2071 indexed citations breakdown →
5.
Hanks, Gerald E. & A.L. Hanlon. (2004). The impact of radiation dose on survival following conformal treatment of prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 60(1). S168–S169. 1 indexed citations
6.
Vicini, Frank A., Alvaro A. Martinez, Gerald E. Hanks, et al.. (2002). An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow‐up. Cancer. 95(10). 2126–2135. 42 indexed citations
7.
Horwitz, Eric M., et al.. (2002). Late morbidity profiles in prostate cancer patients treated to 79–84 Gy by a simple four-field coplanar beam arrangement. International Journal of Radiation Oncology*Biology*Physics. 55(1). 71–77. 50 indexed citations
8.
Jani, Ashesh B., Florin Vaida, Gerald E. Hanks, et al.. (2001). Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate‐specific antigen (PSA), stage, and grade trends in the PSA era. International Journal of Cancer. 96(6). 363–371. 46 indexed citations
9.
Campbell, Timothy, John C. Blasko, E. David Crawford, et al.. (2001). Clinical staging of prostate cancer: Reproducibility and clarification of issues. International Journal of Cancer. 96(3). 198–209. 19 indexed citations
10.
Pilepich, M.V., Roger W. Byhardt, J Mesić, et al.. (2000). Androgen ablation adjuvant to defintive radiotherapy in carcinoma of the prostate: year 2000 update of RTOG phase III studies 86-10 and 85-31. International Journal of Radiation Oncology*Biology*Physics. 48(3). 169–169. 7 indexed citations
11.
Lattanzi, Joseph, Shawn McNeeley, Elizabeth Palacio, et al.. (2000). Ultrasound-Based Stereotactic Guidance in Prostate Cancer—Quantification of Organ Motion and Set-Up Errors in External Beam Radiation Therapy. Computer Aided Surgery. 5(4). 289–295. 30 indexed citations
12.
D’Amico, Anthony V. & Gerald E. Hanks. (1999). Radiotherapeutic management of prostate adenocarcinoma. 7 indexed citations
13.
Hanlon, Alexandra L., et al.. (1998). A gleason score of 7 predicts a worse outcome for prostate carcinoma patients treated with radiotherapy. Cancer. 83(5). 971–976. 41 indexed citations
14.
15.
Hanlon, Alexandra L., Timothy E. Schultheiss, Margie Hunt, et al.. (1997). Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. International Journal of Radiation Oncology*Biology*Physics. 38(1). 59–63. 106 indexed citations
16.
Kutcher, Gerald J., et al.. (1996). Treatment planning for primary breast cancer: A patterns of care study. International Journal of Radiation Oncology*Biology*Physics. 36(3). 731–737. 34 indexed citations
17.
Soffen, Edward, Gerald E. Hanks, Margie Hunt, & Barry E. Epstein. (1992). Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. International Journal of Radiation Oncology*Biology*Physics. 24(3). 485–488. 128 indexed citations
18.
Owen, Jean B., Lawrence R. Coia, & Gerald E. Hanks. (1992). Recent patterns of growth in radiation therapy facilities in the United States: A patterns of care study report. International Journal of Radiation Oncology*Biology*Physics. 24(5). 983–986. 46 indexed citations
19.
Hanks, Gerald E.. (1988). Radical prostatectomy or radiation therapy for early prostate cancer. Two roads to the same end. Cancer. 61(11). 2153–2160. 29 indexed citations
20.
Pilepich, Miljenko V., Richard J. Johnson, Carlos A. Perez, et al.. (1987). Prognostic significance of nodal involvement in locally advanced (stage C) carcinoma of prostate—RTOG experience. Urology. 30(6). 535–540. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alvaro A. Martinez Breakdown of academic impact, for papers by Michael J. Zeléfsky Breakdown of academic impact, for papers by William U. Shipley Breakdown of academic impact, for papers by Ennapadam Venkatraman Breakdown of academic impact, for papers by William T. Sause Breakdown of academic impact, for papers by David P. Dearnaley Breakdown of academic impact, for papers by M. Bolla Breakdown of academic impact, for papers by Luís Souhami Breakdown of academic impact, for papers by Guy Storme Breakdown of academic impact, for papers by Anthony L. Zietman
Rankless by CCL
2026